top of page
Screenshot 2023-10-02 at 12.04.31 PM.png
VictimsJusticeGroup-Logos-121621-TM-02.webp

Ozempic® Injury and Illness Helpline

If you or a loved one suffered injury or illness after taking Ozempic®, you may qualify for financial compensation.

shutterstock_2304339237.jpg

About Ozempic®

According to the CDC, diabetes affects a significant portion of the American population, with over 37 million individuals diagnosed, roughly equating to one in ten people. Among these cases, approximately 90-95% are classified as type 2 diabetes. While type 2 diabetes typically manifests in individuals aged 45 and older, an alarming trend is the increasing incidence of this condition among children, teenagers, and young adults.

 

Jesper Lau, the Vice President of Diabetes Protein & Peptide Chemistry at Novo Nordisk, is credited with the discovery of semaglutide, the active ingredient in Ozempic. This innovative medication was developed as a solution for once-weekly injections.

 

Despite its recent introduction to the medical field, Ozempic's development dates back to 2012. It received approval for the treatment of Type 2 Diabetes five years later, and in 2021, it gained approval as a weight loss aid. This endorsement followed extensive clinical trials that demonstrated its effectiveness in weight management.
 

In contrast to many other Type 2 Diabetes medications, Ozempic is exclusively available in injectable form, provided in prefilled pens, and can only be obtained with a physician's prescription. It is administered subcutaneously under the skin, with injection sites including the thigh, upper arm, or abdomen.

 

Since its introduction, Ozempic has achieved remarkable success, with total sales surpassing $8 billion. According to DrugAnalyst.com and Novo Nordisk Annual/Quarterly Reports, U.S. sales demonstrated significant growth, with figures of $227 million in 2018, $1.3 billion in 2019, $2.3 billion in 2020, $3.2 billion in 2021, and $1.06 billion in Q1 2022.

shutterstock_2160289789.jpg

Complications from Ozempic®

In April 2022, NEJM published data from a study including semaglutide (Ozempic). GLP-1 (glucagon-like peptide 1 receptor agonists) treatment was associated with significant 37% excess relative risk for gallbladder disease or biliary diseases (i.e., stone, obstruction, stenosis, colic, fistula, cyst, or cholangitis).


Biliary disease refers to diseases affecting the bile ducts, gallbladder and other structures involved in the production and transportation of bile. Bile is a fluid produced by the liver that aids digestion.


Injuries that may be associated with Ozempic include:

• Bile Duct Damage
• Bile Duct/Biliary Disease
• Cholelithiasis (Gallstones)
• Gallbladder Disease
• Cholecystitis (Inflammation of the Gallbladder)
• Cholecystectomy (Surgical Removal of the Gallbladder)
• Biliary Cholangitis (Destruction of Bile Ducts in Liver)
• Irreversible Scarring of Liver Tissue (Cirrhosis)
• Liver Failure
• Death Due to Liver Failure

shutterstock_1075819205.jpg

About the Lawsuit

If you or a loved one suffered injury or illness after taking Ozempic®, you may be entitled to significant financial compensation. Fill out the form above to find out.

PAID ATTORNEY ADVERTISEMENT: This Webpage is a group advertisement. It is not a lawyer referral service. Victimsjusticegroup.com/ozempic is owned and operated by Case Legal Media and is not a law firm. We connect people to legal service and there is no charge to be connected with an attorney. You are under no obligation to retain any services of those connected through our website. We try our best to keep things fair and balanced to help you make the best choice for you. This information does not constitute legal or medical advice and it should not be relied upon as such. 

bottom of page